Ionis Pharmaceuticals (IONS) Cash & Current Investments (2009 - 2026)

Ionis Pharmaceuticals' Cash & Current Investments history runs 18 years deep, the most recent figure standing at $2.1 billion for Q2 2026.

• In Q2 2026, Cash & Current Investments fell 10.28% year-over-year to $2.1 billion; the TTM figure through Jun 2026 stood at $2.1 billion (down 10.28% YoY), while the FY2025 annual figure was $2.7 billion, up 16.53% from the prior year.
• Cash & Current Investments for Q2 2026 stood at $2.1 billion, up from $1.9 billion in the prior quarter.
• The five-year high for Cash & Current Investments was $2.7 billion in Q4 2025, with the low at $1.9 billion in Q1 2026.
• The 5-year median for Cash & Current Investments is $2.2 billion (2023), against an average of $2.2 billion.
• The sharpest annual moves came in 2023 and 2024: Cash & Current Investments advanced 17.98% in 2023, then declined 12.86% in 2024.
• Ionis Pharmaceuticals' Cash & Current Investments stood at $2.0 billion in 2022, then climbed by 17.33% to $2.3 billion in 2023, then slipped by 1.44% to $2.3 billion in 2024, then gained by 16.53% to $2.7 billion in 2025, then dropped by 23.26% to $2.1 billion in 2026.
• Business Quant data shows IONS's Cash & Current Investments at $2.1 billion in Q2 2026, $1.9 billion in Q1 2026, and $2.7 billion in Q4 2025.